COVID 19: ICT, Lasa realise success in Favipiravir drug synthesis, to commence production
COVID 19: ICT, Lasa realise success
in Favipiravir drug synthesis,
to commence production
Mumbai, June 17, 2020: Veterinary API Major, Lasa Supergenerics and Institute
of Chemical Technology had come together in the month of March 2020 in effort
to bring the antiviral to the market as a promising therapy to fight the
ongoing Covid-19 pandemic.
Commenting
on the development, Dr Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said Efforts over the last few months has brought success and we
are looking to manufacture close to 10,000 doses to begin with and in the
meanwhile also apply for the drug licence with competent authorities and
continue to seek strategic private investments or Government aid. Our move into
human steroid API is in line with the organisations inherent strengths and
objectives to diversify.
Commenting
on the antivirals successful synthesis, Prof. Vikas N Telvekar, ICT, Mumbai, said
we are happy to share with you that the Favipiravir molecule has been
successfully synthesized in the ICT laboratory on a lab scale and further pilot
plan scale up is required.”
Recently
in its Q4 results, the company reported a healthy increase in its PAT to Rs
3.63 cr for FY20, as compared to a loss of Rs 12.04 cr in the corresponding
period last fiscal
About
ICT, Institute of Chemical Technology (ICT) Formerly the University
Department of Chemical Technology (UDCT) is a Public deemed University
specialized in Chemical Technology located in Mumbai, India. It is focused in
training and research in various branches of chemical engineering, chemical
technology and pharma
Comments
Post a Comment